Science Daily: Pharmacology News
JUNE 23, 2024
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
Drug Patent Watch
JUNE 23, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are listed for this compound.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drugs.com
JUNE 23, 2024
SUNDAY, June 23, 2024 — When a couple can't get pregnant, the focus is often on the prospective mom, but that needs to change, a Houston urologist says."Both partners need evaluation," said Dr. Larry Lipschultz, a professor of urology at Baylor C.
Drug Patent Watch
JUNE 23, 2024
MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
FDA Law Blog: Biosimilars
JUNE 23, 2024
By John A. Gilbert & Karla L. Palmer — For more than 50 years, the Drug Enforcement Administration (DEA) has enforced the central mandate of the Controlled Substances Act (CSA) to maintain a closed chain of distribution for drugs with a potential for abuse and diversion. The CSA and regulations promulgated by DEA are intended to reduce the potential for diversion and abuse and ensure that controlled substances are dispensed and delivered to patients for a legitimate medical purpose.
Drug Patent Watch
JUNE 23, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long time needed to obtain regulatory approval for drugs.
Expert insights. Personalized for you.
61 
Let's personalize your content